

## Special Issue

# Type 2 Diabetes and Cardiovascular Disease: Pathophysiological Mechanisms and Effects of SGLT-2i and GLP-1RAs

### Message from the Guest Editors

Type 2 diabetes (T2DM) is an independent risk factor for ischemic heart disease, stroke, and heart failure, and cardiovascular diseases (CVD) are the main cause of mortality and morbidity in patients with T2DM. The prevention of cardiovascular events is a key goal in the management of patients with T2DM. Recent evidence from cardiovascular outcomes trials (CVOTs) demonstrated the benefits of the new classes of antihyperglycemic drugs—sodium-glucose-cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists—on the cardiovascular outcomes. However, the mechanisms through which treatments with SGLT-2i and GLP-1RAs are associated with an improvement in cardiovascular outcomes are not fully understood. This Special Issue aims to publish original research and review articles concerning significant findings in the field of type 2 diabetes and CVD, in order to explore more processes that contribute to a better understanding of the pathophysiology of cardiovascular disease in patients with T2DM and to learn about new research on the CV protection mechanisms of SGLT-2i and GLP-1RAs.

### Guest Editors

Prof. Dr. Elena Succurro

Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy

Prof. Dr. Angela Sciacqua

1. Associate Professor of Internal Medicine, Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
2. National Abilitation to Full Professor of Internal Medicine, 88100 Catanzaro, Italy
3. Director of Specialization School in Geriatrics, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
4. Director of Geriatric Division – Mater Domini University Hospital-Catanzaro, 88100 Catanzaro, Italy

### Deadline for manuscript submissions

closed (31 January 2022)



## International Journal of Molecular Sciences

an Open Access Journal  
by MDPI

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/70829](https://mdpi.com/si/70829)

*International Journal of  
Molecular Sciences*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[ijms@mdpi.com](mailto:ijms@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[ijms](https://ijms.mdpi.com)





# International Journal of Molecular Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
ijms](https://mdpi.com/journal/ijms)



## About the Journal

### Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

---

### Editor-in-Chief

Prof. Dr. José L. Quiles  
Department of Physiology, Institute of Nutrition and Food Technology  
"Jose Mataix", Biomedical Research Center, University of Granada,  
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)